Five-year Clinical Effects of Donor Bone Marrow Cells Infusions in Kidney Allograft Recipients: Improved Graft Function and Higher Graft Survival

Overview

Journal Chimerism

Specialties General Surgery
Molecular Biology

Date 2013 May 4

PMID 23639966

Citations 1

Authors

Ghasem Solgi

Vijayakrishna Gadi

Biswajit Paul

Joannis Mytilineos

Gholamreza Pourmand

Abdolrasoul Mehrsai

Moslem Ranjbar

Mousa Mohammadnia

Behrouz Nikbin

Ali Akbar Amirzargar

Affiliations

Soon will be listed here.

Abstract

Augmentation of microchimerism in solid organ transplant recipients by donor bone marrow cells (DBMC) infusion may promote immune hyporesponsiveness and consequently improve long-term allograft survival. Between March 2005 and July 2007, outcomes for 20 living unrelated donor (LURD) primary kidney recipients with concurrent DBMC infusion (an average of 2.19 ± 1.13 x 10⁹ donor cells consisting of 2.66 ± 1.70 x 10⁷ CD34⁺ cells) were prospectively compared with 20 non-infused control allograft recipients given similar conventional immunosuppressive regimens. With five years of clinical follow up, a total of 11 cases experienced rejection episodes (3 DBMI patients vs. 8 controls, p = 0.15). One DBMC-infused patient experienced chronic rejection vs. two episodes (1 biopsy-confirmed) in the control patients. Actuarial and death-censored 5-y graft survival was significantly higher in infused patients compared with controls (p = 0.01 and p = 0.03, respectively). Long-term graft survival was significantly associated with pre-transplant anti-HLA antibodies (p = 0.01), slightly with peripheral microchimerism (p = 0.09) and CD4⁺CD25⁺FoxP3⁺ T cells (p = 0.09). Immunosuppressant dosing was lower in infused patients than controls, particularly for mycophenolate mofetil (p = 0.001). The current findings as well as our previous reports on these patients indicates clinical improvement in long-term graft survival of renal transplant patients resulting from low-dose DBMC infusion given without induction therapy.

Citing Articles

Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect?.

Cunningham E, Sharland A, Bishop G Clin Dev Immunol. 2013; 2013:419692.

PMID: 24307909 PMC: 3836300. DOI: 10.1155/2013/419692.

References

Shapiro R, Starzl T . Bone marrow augmentation in renal transplant recipients. Transplant Proc. 1998; 30(4):1371-4. PMC: 2954780. DOI: 10.1016/s0041-1345(98)00279-6. View

Garcia-Morales R, Esquenazi V, Zucker K, Gomez C, Fuller L, Carreno M . An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation. 1996; 62(8):1149-60. DOI: 10.1097/00007890-199610270-00021. View

Loupy A, Hill G, Jordan S . The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012; 8(6):348-57. DOI: 10.1038/nrneph.2012.81. View

Hirt-Minkowski P, Roth M, Honger G, Amico P, Hopfer H, Schaub S . Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int. 2012; 26(1):75-83. DOI: 10.1111/j.1432-2277.2012.01578.x. View

Spitzer T, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S . Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation. 1999; 68(4):480-4. DOI: 10.1097/00007890-199908270-00006. View

Langan L, Park L, Hughes T, Irish A, Luxton G, Witt C . Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant. 2007; 7(4):847-56. DOI: 10.1111/j.1600-6143.2006.01691.x. View

Cirocco R, Carreno M, Mathew J, Garcia-Morales R, Fuller L, Esquenazi V . FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion. Transplantation. 2007; 83(12):1611-9. DOI: 10.1097/01.tp.0000266908.37446.02. View

Solgi G, Furst D, Mytilineos J, Pourmand G, Amirzargar A . Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol. 2011; 26(2-3):81-7. DOI: 10.1016/j.trim.2011.12.002. View

Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico F, Wong W, Schoenfeld D . Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int. 2005; 18(5):532-40. DOI: 10.1111/j.1432-2277.2005.00085.x. View

10.

Garcia-Morales R, Carreno M, Mathew J, Cirocco R, Zucker K, Ciancio G . Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation. 1998; 65(7):956-65. DOI: 10.1097/00007890-199804150-00016. View

11.

Lechler R, Garden O, Turka L . The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003; 3(2):147-58. DOI: 10.1038/nri1002. View

12.

Shapiro R, Rao A, Fontes P, Jordan M, Scantlebury V, Vivas C . Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation. 1995; 59(2):306-9. PMC: 2953377. DOI: 10.1097/00007890-199501000-00026. View

13.

Ciancio G, Burke G, Garcia-Morales R, Suzart K, Rosen A, Ricordi C . Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation. 2002; 74(4):488-96. DOI: 10.1097/00007890-200208270-00010. View

14.

Fontes P, Rao A, Demetris A, Zeevi A, Trucco M, Carroll P . Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet. 1994; 344(8916):151-5. PMC: 2962586. DOI: 10.1016/s0140-6736(94)92756-1. View

15.

Chen Y, Tai Q, Hong S, Kong Y, Shang Y, Liang W . Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis. Transplantation. 2012; 94(9):911-8. DOI: 10.1097/TP.0b013e31826784ad. View

16.

Ranjbar M, Solgi G, Mohammadnia M, Nikbin B, Pourmand G, Ansaripour B . Regulatory T-cell subset analysis and profile of interleukin (IL)-10, IL-17 and interferon-gamma cytokine-producing cells in kidney allograft recipients with donor cells infusion. Clin Exp Nephrol. 2012; 16(4):636-46. DOI: 10.1007/s10157-012-0591-9. View

17.

Susal C, Dohler B, Opelz G . Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol. 2009; 70(8):569-73. DOI: 10.1016/j.humimm.2009.04.013. View

18.

Worthington J, Martin S, Al-Husseini D, Dyer P, Johnson R . Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003; 75(7):1034-40. DOI: 10.1097/01.TP.0000055833.65192.3B. View

19.

Millan M, Shizuru J, Hoffmann P, Dejbakhsh-Jones S, Scandling J, Grumet F . Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation. 2002; 73(9):1386-91. DOI: 10.1097/00007890-200205150-00005. View

20.

Rao A, Shapiro R, Corry R, DODSON F, Abu-Elmagd K, Jordan M . Adjuvant bone marrow infusion in clinical organ transplant recipients. Transplant Proc. 1998; 30(4):1367-8. PMC: 2950631. DOI: 10.1016/s0041-1345(98)00277-2. View